Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$22.40 USD
-0.14 (-0.62%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $22.46 +0.06 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGEM 22.40 -0.14(-0.62%)
Will CGEM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Cullinan Management’s Zipalertinib Shows Lung Cancer Trial Promise
TD Cowen Sticks to Its Buy Rating for Cullinan Management (CGEM)
Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)
Analysts’ Top Healthcare Picks: Autolus Therapeutics (AUTL), Affimed (AFMD)
Buy Recommendation Backed by Promising Clinical Results for Cullinan Management’s Oncology Drugs